Literature DB >> 15711585

New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarin.

Shannon M Bates1, Jeffrey I Weitz.   

Abstract

The limitations of traditional anticoagulants, heparin and warfarin, have prompted the development of new anticoagulant drugs for prevention and treatment of both venous and arterial thromboembolism. After a brief review of thrombogenesis and its regulation, this paper focuses on new anticoagulant agents in more advanced stages of clinical testing.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15711585      PMCID： PMC1576097          DOI： 10.1038/sj.bjp.0706153

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  118 in total

1.  Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study.

Authors:  J A Bittl; B R Chaitman; F Feit; W Kimball; E J Topol
Journal:  Am Heart J       Date:  2001-12       Impact factor: 4.749

2.  Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement.

Authors:  A Lee; G Agnelli; H Büller; J Ginsberg; J Heit; W Rote; G Vlasuk; L Costantini; J Julian; P Comp; J van Der Meer; F Piovella; G Raskob; M Gent
Journal:  Circulation       Date:  2001-07-03       Impact factor: 29.690

3.  Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

Authors:  A Greinacher; U Janssens; G Berg; M Böck; H Kwasny; B Kemkes-Matthes; P Eichler; H Völpel; B Pötzsch; M Luz
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

4.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.

Authors:  K A Bauer; B I Eriksson; M R Lassen; A G Turpie
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

5.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.

Authors:  B I Eriksson; K A Bauer; M R Lassen; A G Turpie
Journal:  N Engl J Med       Date:  2001-11-01       Impact factor: 91.245

6.  Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.

Authors:  J A Heit; C W Colwell; C W Francis; J S Ginsberg; S D Berkowitz; J Whipple; G Peters
Journal:  Arch Intern Med       Date:  2001-10-08

7.  A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study.

Authors:  P K Coussement; J P Bassand; C Convens; M Vrolix; J Boland; G Grollier; R Michels; A Vahanian; M Vanderheyden; H J Rupprecht; F Van de Werf
Journal:  Eur Heart J       Date:  2001-09       Impact factor: 29.983

8.  Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats.

Authors:  G Z Feuerstein; A Patel; J R Toomey; P Bugelski; A J Nichols; W R Church; R Valocik; P Koster; A Baker; M N Blackburn
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-10       Impact factor: 8.311

9.  Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

Authors:  E Abraham; K Reinhart; P Svoboda; A Seibert; D Olthoff; A Dal Nogare; R Postier; G Hempelmann; T Butler; E Martin; C Zwingelstein; S Percell; V Shu; A Leighton; A A Creasey
Journal:  Crit Care Med       Date:  2001-11       Impact factor: 7.598

10.  Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.

Authors:  N Murayama; M Tanaka; S Kunitada; H Yamada; T Inoue; Y Terada; M Fujita; Y Ikeda
Journal:  Clin Pharmacol Ther       Date:  1999-09       Impact factor: 6.875
View more
  9 in total

1.  Development of oral anticoagulants.

Authors:  Qing Ma
Journal:  Br J Clin Pharmacol       Date:  2007-05-15       Impact factor: 4.335

2.  New treatment options for stroke prevention in atrial fibrillation.

Authors:  Benjamin Rhee; Richard L Page
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-10

Review 3.  The evolution of anticoagulant therapy.

Authors:  Massimo Franchini; Giancarlo M Liumbruno; Carlo Bonfanti; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2015-12-16       Impact factor: 3.443

Review 4.  Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery.

Authors:  Bengt I Eriksson; Daniel J Quinlan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Dalteparin vs low-dose unfractionated heparin for prophylaxis against clinically evident venous thromboembolism in acute traumatic spinal cord injury: a retrospective cohort study.

Authors:  Scott Worley; Christine Short; Jeff Pike; David Anderson; Jo-Anne Douglas; Kara Thompson
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

6.  M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice.

Authors:  Subrata Chakrabarti; Lea M Beaulieu; Lara A Reyelt; Mark D Iafrati; Jane E Freedman
Journal:  J Thromb Thrombolysis       Date:  2009-11       Impact factor: 2.300

7.  Case files of the Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, AZ: a non-warfarin anticoagulant overdose.

Authors:  Chip Gresham; Michael Levine; Anne-Michelle Ruha
Journal:  J Med Toxicol       Date:  2009-12

8.  Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Arthroplasty: Changing Trends.

Authors:  Nicolaas C Budhiparama; Matthew P Abdel; Nadia N Ifran; Sébastien Parratte
Journal:  Curr Rev Musculoskelet Med       Date:  2014-06

Review 9.  Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.

Authors:  Anna Lichota; Eligia M Szewczyk; Krzysztof Gwozdzinski
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.